Human immunodeficiency virus (HIV) in developing countries

Annals of Tropical Medicine and Parasitology

Volumn 100, Issue 5-6, 2006, Pages 433-454

  French, N ^a   Kaleebu, P ^b   Pisani, E ^c   Whitworth, J A G ^d  

^a KARONGA PREVENTION STUDY   (Malawi)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BENFLUMETOL; CARAGEENAN; CELLULOSE SULFATE; COTRIMOXAZOLE; DAPIVIRINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NONOXINOL 9; PRO 2000; PROTEINASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MONITORING; EPIDEMIC; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; MONOTHERAPY; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PREVALENCE; REVIEW; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; AIDS RELATED COMPLEX;

HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE;

EID: 33750060364     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/136485906X97390     Document Type: Review

References (129)

1. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M. & Berger, E. A. (1996). CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 272, 1955-1958.
2. Allen, S., Meinzen-Derr, J., Kautzman, M., Zulu, I., Trask, S., Fideli, U., Musonda, R., Kasolo, F., Gao, F. & Haworth, A. (2003). Sexual behaviour of HIV discordant couples after HIV counselling and testing. AIDS, 17, 733-740.
3. Anglaret, X., Chene, G., Attia, A., Toure, S., Lafont, S., Combe, P., Manlan, K., N'Dri-Yoman, T. & Salamon, R (1999). Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet, 353, 1463-1468.
4. Anglaret, X., Messou, E., Ouassa, T., Toure, S., Dakoury-Dogbo, N., Combe, P., Mahassadi, A., Seyler, C., N'Dri-Yoman, T., Salamon, R. & ANRS 1203 Study Group (2003). Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire. AIDS, 17, 575-584.
5. Anon. (2001). Declaration of Commitment on HIV/AIDS: Global Crisis - Global Action. New York, NY: United Nations.
6. Anon. (2002). Estimating the Size of Populations at Risk for HIV: Issues and Methods, a Joint UNAIDS/IMPACT/FHI Workshop: Report and Conclusions. Research Triangle Park, NC: Family Health International.
7. Anon. (2004). AIDS in Asia: Face the Facts. Bangkok: Monitoring the AIDS Pandemic (MAP).
8. Anon. (2005a). AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS.
9. Anon. (2005b). Intensifying HIV Prevention. Geneva: Joint United Nations Programme on HIV/AIDS.
10. Anon. (2005c). Guidelines on Estimating the Size of Populations at Risk for and Infected with HIV. Jakarta: Directorate General of Communicable Disease Control and Environmental Health.
11. Anon. (2006). 2005: year in review. Vax, 4, unnumbered.
12. Anzala, O. A., Ball, T. B., Rostron, T., O'Brien, S. J., Plummer, F. A., Rowland-Jones, S. L. & University of Nairobi Collaboration for HIV Research (1998). CCR2-641 allele and genotype association with delayed AIDS progression in African women. Lancet, 351, 1632-1633.
13. Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R. & Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Medicine, 2, e298.
14. Bass, E. (2005). The two sides of PEPFAR in Uganda. Lancet, 365, 2077-2078.
15. Bayer, R. (1991). Public health policy and the AIDS epidemic. An end to HIV exceptionalism? New England Journal of Medicine, 324, 1500-1504.
16. Blower, S., Bodine, E., Kahn, J. & McFarland, W. (2005). The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS, 19, 1-14.
17. Boerma, J. T., Ghys, P. & Walker, N. (2003). HIV estimates from national population-based surveys as a new gold standard. Lancet, 362, 1929-1931.
18. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. Journal of Virology, 68, 6103-6110.
19. Cao, H., Kaleebu, P., Horn, D., Flores, J., Agrawal, D., Jones, N., Serwanga, J., Okello, M., Walker, C., Sheppard, H., El-Habib, R., Klein, M., Mbidde, E., Mugyenyi, P., Walker, B., Ellner, J., Mugerwa, R. & The HIV Network for Prevention Trials (2003). Immunogenicity of a recombinant human immunodeficiency virus (HIV) canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. Journal of Infectious Diseases, 187, 887-895.
20. Cocchi, F., de Vico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. & Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV suppressive factors produced by CD4+ T cells. Science, 270, 1811-1815.
21. Coetzee, D., Hildebrand, K., Boulle, A., Maartens, G., Louis, F., Labatala, V., Reuter, H., Ntwana, N. & Goemaere, E. (2004). Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS, 18, 887-895.
22. Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C. & Corey, L. (1996). Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. New England Journal of Medicine, 334, 1011-1017.
23. Corbett, E. L., Churchyard, G. J., Charalambos, S., Samb, B., Moloi, V., Clayton, T. C., Grant, A. D., Murray, J., Hayes, R. J. & De Cock, K. M. (2002). Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clinical Infectious Diseases, 34, 1251-1258.
24. Dalgleish, A. G., Beverly, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F. & Weiss, R. (1984). CD4(T4) antigen is an essential component of the receptor for AIDS retrovirus. Nature, 312, 763-767.
25. De Cock, K. M., Mbori-Ngacha, D. & Marum, E. (2002). Shadow on the continent: public health and HIV/AIDS in Africa in the 21st Century. Lancet, 360, 67-72.
26. De Cock, K. M., Marum, E. & Mbori-Ngacha, D. (2003). A serostatus-based approach to HIV/AIDS prevention and care in Africa. Lancet, 362, 1847-1849.
27. De Cock, K. M., Bunnell, R. & Mermin, J. (2006). Unfinished business - expanding HIV testing in developing countries. New England Journal of Medicine, 354, 440-442.
28. Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E., Gomperts, E., Donfield, S., Vlahov, D., Kaslow, R., Saah, A., Rinaldo, C., Detels, R. & O'Brien, S. J. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a common deletion allele of the chemokine receptor 5 structural gene. Science, 273, 1856-1962.
29. Diaz, T., De Cock, K., Brown, T., Ghys, P. D. & Boerma, J. T. (2005a). New strategies for HIV surveillance in resource-constrained settings: an overview. AIDS, 19 (Suppl. 2), S1-S8.
30. Diaz, T., Loth, G., Whitworth, J. & Sutherland, D. (2005b). Surveillance methods to monitor the impact of HIV therapy programmes in resource-constrained countries. AIDS, 19 (Suppl. 2), S31-S37.
31. Diomande, F. V., Bissagnene, E., Nkengasong, J. N., Maurice, C., Monga, B., Laga, M. & Nolan, M. L. (2003). The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire's Drug Access Initiative. AIDS, 17 (Suppl. 3), S87-S93.
32. Dowling, W. E., Kim, B., Mason, C. J., Wasunna, K. M., Alam, U., Elson, L., Birx, D. L., Robb, M. L., McCutchan, F. E. & Carr, J. K. (2002). Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS, 16, 1809-1820.
33. Feng, Y., Brider, C. C., Kennedy, P. E. & Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 272, 872-877.
34. Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J. L., Duliege, A. M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proceedings of the National Academy of Sciences of the United States of America, 94, 1396-1401.
35. Fleming, D. T. & Wasserheit, J. N. (1999). From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sexually Transmitted Infections, 75, 3-17.
36. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H. & Para, MF; The rgp120 HIV Vaccine Study Group (2005). Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases, 191, 654-665.
37. Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A. & Hayes, R. J. (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS, 20, 73-83.
38. French, N., Mujugira, A., Nakiyingi, J., Mulder, D., Janoff, E. N. & Gilks, C. F. (1999). Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. Journal of Acquired Immune Deficiency Syndromes, 22, 509-516.
39. French, N., Nakiyingi, J., Carpenter, L. M., Lugada, E., Watera, C., Moi, K., Moore, M., Antvelink, D., Mulder, D., Janoff, E. N., Whitworth, J. & Gilks, C. F. (2000). 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet, 355, 2106-2111.
40. French, N., Nakiyingi, J., Lugada, E., Watera, C., Whitworth, J. A. G. & Gilks, C. F. (2001). Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS, 15, 899-906.
41. French, N., Gray, K., Watera, C., Nakiyingi, J., Lugada, E., Moore, M., Lalloo, D., Whitworth, J. A. G. & Gilks, C. F. (2002). Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 16, 1031-1038.
42. Frieden, T. R., Das-Douglas, M., Kellerman, S. E. & Henning, K. J. (2005). Applying public health principles to the HIV epidemic. New England Journal of Medicine, 353, 2397-2402.
43. Garcia-Calleja, J. M., Zaniewski, E., Ghys, P. D., Stanecki, K. & Walker, N. (2004). A global analysis of trends in the quality of HIV sero-surveillance. Sexually Transmitted Infections, 80 (Suppl. 1), 125-130.
44. Gilks, C. F., Ojoo, S. A., Ojoo, J. C., Brindle, R. J., Paul, J., Batchelor, B. I., Kimari, J. N., Newnham, R., Bwayo, J., Plummer, F. A. & Warrell, D. A. (1996). Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet, 347, 718-723.
45. Girardi, E., Sabin, C. A., d'Arminio Monforte, A., Hogg, B., Phillips, A. N., Gill, M. J., Dabis, F., Reiss, P., Kirk, O., Bernasconi, E., Grabar, S., Justice, A., Staszewski, S., Fatkenheuer, G. & Sterne, J. A. (2005). Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases, 41, 1772-1782.
46. Grant, A. D., Djomand, G. & De Cock, K. M. (1997). Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS, 11, s43-s54.
47. Grant, A. D., Kaplan, J. E. & De Cock, K. M. (2001). Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries. American Journal of Tropical Medicine and Hygiene, 65, 810-821.
48. Gray, R. H., Wawer, M. J., Brookmeyer, R., Sewankambo, N. K., Serwadda, D., Wabwire-Mangen, F., Lutalo, T., Li, X., van Cott, T. & Quinn, T. C. (2001). Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet, 357, 1149.
49. Gray, R. H., Li, X., Wawer, M. J., Gange, S. J., Serwadda, D., Sewankambo, N. K., Moore, R., Wabwire-Mangen, F., Lutalo, T. & Quinn, T. C. (2003). Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS, 17, 1941-1951.
50. Gregson, S., Nyamukapa, C. A., Garnett, G. P., Mason, P. R., Zhuwau, T., Carael, M., Chandiwana, S. K. & Anderson, R. M. (2002). Sexual mixing patterns and sex-differentials in teen-age exposure to HIV infection in rural Zimbabwe. Lancet, 359, 1896-1903.
51. Gregson, S., Garnett, G. P., Nyamukapa, C. A., Hallett, T. B., Lewis, J. J., Mason, P. R., Chandiwana, S. K. & Anderson, R. M. (2006). HIV decline associated with behavior change in eastern Zimbabwe. Science, 311, 620-621.
52. Grimwade, K. & Gilks, C. (2001). Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Current Opinion in Infectious Diseases, 14, 507-512.
53. Grosskurth, H., Mosha, F., Todd, J., Mwijarubi, E., Klokke, A., Senkoro, K., Mayaud, P., Changalucha, J., Nicholl, A., Ka-Gina, G., Newell, J., Mugeye, K., Mabey, D. & Hayes, R. (1995). Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet, 346, 530-536.
54. Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., McNeil, A. & Dandekar, S. (2003). Severe CD4 T cells depletion in the gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. Journal of Virology, 77, 11,708-11,717.
55. Guay, L. A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Ducar, C., Deseyve, M., Emel, L., Mirochnick, M., Fowler, M. G., Mofenson, L., Miotti, P., Dransfield, K., Bray, D., Mmiro, F. & Jackson, J. B. (1999). Intrapartum and neonatal single-dose nevirapine compared to zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 354, 795-802.
56. Hahn, B. H., Shaw, G. M., De Cock, K. M. & Sharp, P. M. (2000). AIDS as a zoonosis: scientific and public health implications. Science, 287, 607-614.
57. Heffernan, R. T., Barrett, N. L., Gallagher, K. M., Hadler, J. L., Harrison, L. H., Reingold, A. L., Khoshnood, K., Holford, T. R. & Schuchat, A. (2005). Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. Journal of Infectious Diseases, 191, 2038-2045.
58. Hoelscher, M., Dowling, W. E., Sanders-Buell, E., Carr, J. K., Harris, M. E., Thomschke, A., Robb, M. L., Birx, D. L. & McCutchan, F. E. (2002). Detection of HIV-1 subtypes, recombinants, and dual infections in East Africa by a multi-region hybridization assay. AIDS, 16, 2055-2064.
59. Hogan, D. R., Baltussen, R., Hayashi, C., Lauer, J. A. & Salomon, J. A. (2005). Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Lancet, 331, 1431-1435.
60. Janssen, R. S., Satten, G. A., Stramer, S. L., Rawal, B. D., O'Brien, T. R., Weiblen, B. J., Hecht, F. M., Jack, N., Cleghorn, F. R., Kahn, J. O., Chesney, M. A. & Busch, M. P. (1998). New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. Journal of the American Medical Association, 280, 42-48.
61. Janssen, R. S., Holtgrave, D. R., Valdiserri, R. O., Shepherd, M., Gayle, H. D. & De Cock, K. M. (2001). The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. American Journal of Public Health, 91, 1019-1024.
62. Kantor, R., Katzenstein, D. A., Efron, B., Carvalho, A. P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M. A., Snoeck, J., Pillay, C., Rudich, H., Rodrigues, R., Holguin, A., Ariyoshi, K., Bouzas, M. B., Cahn, P., Sugiura, W., Soriano, V., Brigido, L. F., Grossman, Z., Morris, L., Vandamme, A. M., Tanuri, A., Phanuphak, P., Weber, J. N., Pillay, D., Harrigan, P. R., Camacho, R., Schapiro, J. M. & Shafer, R. W. (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Medicine, 2, e112.
63. Karnasuta, C., Paris, R. M., Cox, J. H., Nitayaphan, S., Pitisuttithum, P., Thongcharoen, P., Brown, A. E., Gurunafhan, S., Tartaglia, J., Heyward, W. L., McNeil, J. G., Birx, D. L., de Souza, M. S. & TAVEG Thai AIDS Vaccine Evaluation Group, Thailand (2005). Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine, 23, 2522-2529.
64. Kaslow, R. A., Carrington, M., Apple, R., Park, L., Munoz, A., Saah, A. J., Goedert, J. J., Winkler, C., O'Brien, S. J., Rinaldo, C., Detels, R., Blattner, W., Phair, J., Erlich, H. & Mann, D. L. (1996). Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Medicine, 2, 405-411
65. Kassa, E., Rinke de Wit, T. F., Hailu, E., Girma, M., Messele, T., Mariam, H. G., Yohannes, S., Jurriaans, S., Yeneneh, H., Coutinho, R. A. & Fontanet, A. L. (1999). Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS, 13, 381-389.
66. Keele, B. F., van Heuverswyn, F., Li, Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V., Liegeois, F., Loul, S., Mpoudi Ngole, E., Bienvenue, Y., Delaporte, E., Brookfield, J. F. Y., Sharp, P. M., Shaw, G. M., Peeters, M. & Hahn, B. H. (2006). Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science, in press.
67. Khoo, S., Back, D. & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs. AIDS, 19, 995-1005.
68. Kim, J. Y. & Gilks, C. (2005). Scaling up treatment - why we can't wait. New England Journal of Medicine, 352, 2392-2394.
69. Klatzmann, D., Campagne, E., Chamaret, S., Gurest, J., Guetard, D., Hercend, T., Gluckman, J. C. & Montagnier, L. T. (1984). Lymphocyte T4 behaves as the receptor for human retrovirus LAV. Nature, 312, 767-771.
70. Klausner, R. D., Fauci, A. S., Corey, L., Nabel, G. J., Gayle, H., Berkley, S., Haynes, B. F., Baltimore, D., Collins, C., Douglas, R. G., Esparza, J., Francis, D. P., Ganguly, N. K., Gerberding, J. L., Johnston, M. I., Kazatchkine, M. D., McMichael, A. J., Makgoba, M. W., Pantaleo, G., Piot, P., Shao, Y., Tramont, E., Varmus, H. & Wasserheit, J. N. (2003). The need for a global HIV/AIDS vaccine enterprise. Science, 300, 2036-2039.
71. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C. & Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of Virology, 68, 4650-4655.
72. Kreiss, J., Ngugi, E., Holmes, K., Ndinya-Achola, J., Waiyaki, P., Roberts, P. L., Ruminjo, I., Sajabi, R., Kimata, J., Fleming, T. R., Anzala, A., Holton, D. & Plummer, F. (1992). Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. Journal of the American Medical Association, 268, 477-482.
73. Kumar, R., Jha, P., Arora, P., Mony, P., Bhatia, P., Millson, P., Dhingra, D., Bhattacharya, M., Remis, R. S. & Nagelkerke, N., for the International Studies of HIV/AIDS (ISHA) Investigators (2006). Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet, 367, 1164-1172.
74. Lawn, S. D., Badri, M. & Wood, R. (2005a). Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS, 19, 2109-2116.
75. Lawn, S. D., Myer, L., Orrell, C., Bekker, L. G. & Wood, R. (2005b). Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS, 19, 2141-2148.
76. Lehner, T. & Anton, P. A. (2002). Mucosal immunity and vaccination against HIV. AIDS, 16 (Suppl. 4), S125-S132.
77. Levy, J. A., Scott, I. & Mackewicz, C. (2003). Protection from HIV/AIDS: the importance of innate immunity. Clinical Immunology, 108, 167-174.
78. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A. & Landau, N. R. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367-377.
79. Mbulaiteye, S. M., Mahe, C., Whitworth, J. A. G., Ruberwantari, A., Nakiyingi, J. S., Ojwiya, A. & Kamali, A. (2002). Declining HIV-1 incidence and associated prevalence over 10-years in a rural population in south-west Uganda: a cohort study. Lancet, 360, 41-46.
80. Mehandru, S., Poles, M. A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan, C., Boden, D., Racz, P. & Markowitz, M. (2004). Primary HIV-1 infection is associated with preferential depletion of CD4 T lymphocytes from effector sites in the gastrointestinal tract. Journal of Experimental Medicine, 200, 761-770.
81. Migueles, S. A., Sabbaghian, M. S., Shupert, W. L., Bettinotti, M. P., Marincola, F. M., Martino, L., Hallahan, C. W., Selig, S. M., Schwartz, D., Sullivan, J. & Connors, M. (2000). HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-1 infected long term nonprogressors. Proceedings of the National Academy of Sciences of the United States of America, 97, 2709-2714.
82. Mills, E., Rachlis, B., Wu, P., Wong, W., Wilson, K. & Singh, S. (2005). Media reporting of tenofovir trials in Cambodia and Cameroon. BMC International Health and Human Rights, 5, 6.
83. Morgan, D. & Whitworth, J. (2001). The natural history of HIV-1 infection in Africa. Nature Medicine, 7, 143-145.
84. Morgan, D., Maude, G. H., Malamba, S. S., Okongo, M. J., Wagner, H. U., Mulder, D. W. & Whitworth, J. A. (1997). HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet, 350, 245-250.
85. Morris, L., Martin, D. J., Bredell, H., Nyoka, S. N., Sacks, L., Pendle, S., Page-Shipp, L., Karp, C. L., Sterling, T. R., Quinn, T. C. & Chaisson, R. E. (2003). Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. Journal of Infectious Diseases, 187, 1967-1971.
86. Mugerwa, R. D., Kaleebu, P., Mugyenyi, P., Katongole-Mbidde, E., Hom, D. L., Byaruhanga, R., Salata, R. A., Ellner, J. J. & The HIV-1 Vaccine Trial Group (2002). First trial of the HIV-1 vaccine in Africa: Ugandan experience. British Medical Journal, 324, 226-229.
87. Mugisha, E., Nakwagala, F., Konde, C., Johnson, B., Nanvubya, A., Birungi, J., Muluubya, A., Kiwanuka, P., Nielsen, L., Schmidt, C., Fast, P., Thiry, G. & Kaleebu, P. (2006). Community based volunteer recruitment and community involvement: experiences and lessons learnt from the second HIV vaccine trial in Uganda. Journal of Acquired Immune Deficiency Syndromes, in press.
88. Mugyenyi, P. N. (2002). HIV vaccines: the Uganda experience. Vaccine, 20, 1905-1908.
89. Mukheriee, J. S., Farmer, P. E., Niyizonkiza, D., McCorkle, L., Vanderwarker, C., Teixeira, P. & Kim, J. Y. (2003). Tackling HIV in resource poor countries. British Medical Journal, 327, 1104-1106.
90. Orroth, K. K., Korenromp, E. L., White, R. G., Gayvole, A., Gray, R. H., Muhangi, L., Sewankambo, N. K., Quigley, M., Wawer, M. J., Whitworth, J. A. G., Grosskurth, H., Habbema, J. D. F. & Hayes, R. J. (2003). Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. AIDS, 17, 2653-2660.
91. Parekh, B. S., Kennedy, M. S., Dobbs, T., Pau, C. P., Byers, R., Green, T., Hu, D. J., Vanichseni, S., Young, N. L., Choopanya, K., Mastro, T. D. & McDougal, J. S. (2002). Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Research and Human Retroviruses, 18, 295-307.
92. Parkhurst, J. O. (2002). The Ugandan success story? Evidence and claims of HIV-1 prevention. Lancet, 360, 78-80.
93. Peeters, M., Toure-Kane, C. & Nkengasong, J. N. (2003). Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS, 17, 2547-2560.
94. Pilcher, C. D., Tien, H. C., Eron Jr, J. J., Vernazza, P. L., Leu, S. Y., Stewart, P. W., Goh, L. E. & Cohen, M. S., for the Quest Study and the Duke-UNC-Emory Acute HIV Consortium (2004). Brief but efficient: acute HIV infection and the sexual transmission of HIV. Journal of Infectious Diseases, 189, 1785-1792.
95. Pisani, E., Garnett, G. P., Grassly, N. C., Brown, T., Stover, J., Hankins, C., Walker, N. & Ghys, P. D. (2003). Back to basics in HIV prevention: focus on exposure. British Medical Journal, 326, 1384-1387.
96. Pitcher, C. J., Quittner, C., Peterson, D. M., Connors, M., Koup, R. A., Maino, V. C. & Picker, L. J. (1999). HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine, 5, 518-525.
97. Quigley, M. A., Mwinga, A., Hosp, M., Lisse, I., Fuchs, D., Porter, J. D. H. & Godfrey-Faussett, P. (2001). Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 15, 215-22.
98. Richard, N., Juntilla, M., Abraha, A., Demers, K., Paxinos, E., Galovich, J., Petropoulos, C., Whalen, C. C., Kyeyune, F., Atwine, D., Kityo, C., Mugyenyi, P. & Arts, E. J. (2004). High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Research and Human Retroviruses, 20, 355-364.
99. Roddy, R. E., Zekeng, L., Ryan, K. A., Tamoufe, U., Weir, S. S. & Wong, E. L. (1998). A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. New England Journal of Medicine, 339, 504-510.
100. Rosenberg, E. S., Altfeld, M., Poon, S. H., Phillips, M. N., Wilkes, B. M., Eldridge, R. L., Robbins, G. K., D'Aquila, R. T., Goulder, P. J. & Walker, B. D. (2000). Immune control of HIV-1 after early treatment of acute infection. Nature, 407, 523-526.
101. Salomon, J. A., Hogan, D. R., Stover, J., Stanecki, K. A., Walker, N., Ghys, P. D. & Schwartlander, B. (2005). Integrating HIV prevention and treatment: from slogans to impact. PLoS Medicine, 2, e16.
102. Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., Saragosti, S., Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart, G. & Parmentier, M. (1996). Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382, 722-725.
103. Seyler, C., Anglaret, X., Dakoury-Dogbo, N., Messou, E., Toure, S., Danel, C., Diakite, N., Daudie, A., Inwoley, A., Maurice, C., Tonwe-Gold, B., Rouet, F., N'Dri-Yoman, T. & Salamon, R. (2003). Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antiviral Therapy, 8, 385-393.
104. Shelton, J. D., Halperin, D. T., Nantulya, V., Potts, M. & Gayle, H. D. (2004). Partner reduction is crucial for balanced 'ABC' approach to HIV prevention. British Medical Journal, 328, 891-894.
105. Shelton, J. D., Halperin, D. T. & Wilson, D. (2006). Has global HIV incidence peaked? Lancet, 367, 1120-1121.
106. Speelmon, E. C. D., Livingston-Rosanoff, D., Li, S. S., Vu, Q., Bui, J., Geraghty, D. E., Zhao, L. P. & McElrath, M. J. (2006). Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. Journal of Virology, 80, 2463-2471.
107. Stolte, I. G., Dukers, N. H. T. M, de Wit, J. B. F., Fennema, H. & Coutinho, R. A. (2002). A summary report from Amsterdam: increase in sexually transmitted diseases and risky sexual behaviour among homosexual men in relation to the introduction of new anti-HIV drugs. Eurosurveillance, 7, 19-22.
108. Stover, J., Walker, N., Garnett, G. P., Salomon, J. A., Staneki, K. A., Ghys, P. D., Grassly, N. C., Anderson, R. M. & Schwartlander, B. (2002). Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet, 360, 73-77.
109. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S. S., Masse, B., Perriens, J. & Laga, M., on behalf of the COL-1492 Study Group (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet, 360, 971-977.
110. Van Damme, W., Kober, K. & Laga, M. (2006). The real challenges for scaling up ART in sub-Saharan Africa. AIDS, 20, 653-656.
111. Van Oosterhout, J. J., Laufer, M. K., Graham, S. M., Thumba, F., Perez, M. A., Chimbiya, N., Wilson, L., Chagomerana, M., Molyneux, M. E., Zijlstra, E. E., Taylor, T. E. & Plowe, C. V. (2005). A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. Journal of Acquired Immune Deficiency Syndromes, 39, 626-631.
112. Wald, A. & Link, K. (2002). Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. Journal of Infectious Diseases, 185, 45-52.
113. Wasserheit, J. N. (1992). Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sexually Transmitted Diseases, 19, 61-77.
114. Watera, C., Whitworth, J. A. G., Muwonge, R., Todd, J., Nakiyingi, J., Brink, A., Miiro, G., Antvelink, L., Kamali, A., French, N. & Mermin, J. (2006). Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. Journal of Acquired Immune Deficiency Syndromes, in press.
115. Wawer, M. J., Serwadda, D., Li, X., Quinn, T. C., Sewankambo, N. K., Kiwanuka, N., Kigozi, G. & Gray, R. H. (2003). HIV-1 transmission per coital act, by stage of HIV Infection in the HIV+ index partner, in discordant couples, Rakai, Uganda. In 10th Conference on Retroviruses and Opportunistic Infections, abstract 40 (www.retroconference.org/2003/cd/Abstract/40.htm). Alexandria, VA: Foundation for Retrovirology and Human Health.
116. Weber, J., Desai, K. & Darbyshire, J., on behalf of the Microbicide Development Programme. (2005). The development of vaginal microbicides for prevention of HIV transmission. PloS Medicine, 2, e142.
117. Weidle, P. J., Malamba, S., Mwebaze, R., Sozi, C., Rukundo, G., Downing, R., Hanson, D., Ochola, D., Mugyenyi, P., Mermin, J., Samb, B. & Lackritz, E. (2002). Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet, 360, 34-40.
118. Whalen, C. C., Johnson, J. L., Okwera, A., Horn, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D. & Ellner, J. J. (1997). A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. New England Journal of Medicine, 337, 801-808.
119. Wiktor, S. Z., Sassan-Morokro, M., Grant, A. D., Abouya, L., Karon, J. M., Maurice, C., Djomand, G., Ackah, A., Domoua, K., Kadio, A., Yapi, A., Combe, P., Tossou, O., Roels, T. H., Lackritz, E. M., Coulibaly, D., De Cock, K. M., Coulibaly, I. M. & Greenberg, A. E. (1999). Efficacy of trimethoprim- sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet, 353, 1469-1475.
120. World Health Organization (2000). Guidelines for Second Generation HIV Surveillance. Document WHO/CDS/EDC/2000.05. Geneva: WHO.
121. World Health Organization (2002). Prevention of HIV in Infants and Young Children. Review of Evidence and WHO's Activities. Document WHO/HIV/2002.08. Geneva: WHO.
122. World Health Organization (2004). Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Guidelines on Care, Treatment and Support for Women Living with HIV/AIDS and their Children in Resource-constrained Settings. Geneva: WHO.
123. World Health Organization (2005a). '3 by 5' Progress Report, June 2005. Geneva: WHO.
124. World Health Organization (2005b). Progress on Global Access to HIV Antiretroviral Therapy: an Update on '3 by 5'. Geneva: WHO.
125. World Health Organization (2006a). WHO Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection. Technical Report Series. Geneva: WHO.
126. World Health Organization (2006b). Global Access to HIV Therapy Tripled in past Two Years, but Significant Challenges Remain. Geneva: WHO.
127. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K. & Pathak, V. K. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the United States of America, 101, 5652-5657.
128. Yirrell, D., Kaleebu, P., Mogan, D., Watera, C., Magambo, B., Lyagoba, F. & Whitworth, J. (2002). Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS, 16, 279-286.
129. Zachariah, R., Teck, R., Ascurra, O., Humblet, P. & Harries, A. D. (2006). Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treatment and costs in Thyolo district, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 24-31.